|
[1]CROXFORD AL,KULIG P,BECHER B.IL-12 and IL-23 in health and disease[J].Cytokine Growth Factor Rev,2014,25(4):415-421.
|
|
[2]OPPMANN B,LESLEY R,BLOM B,et al.Novel p19 protein engages IL-12p40 to form a cytokine,IL-23,with biological activities similar as well as distinct from IL-12[J].Immunity,2000,13(5):715-725.
|
|
[3]MORELLI AE,ZAHORCHAK AF,LARREGINA AT,et al.Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation[J].Blood,2001,98(5):1512-1523.
|
|
[4]ABRAHAM C,CHO JH.IL-23 and autoimmunity:new insights into the pathogenesis of inflammatory bowel disease[J].Annu Rev Med,2009,60:97-110.
|
|
[5]HUANG Z,van VELKINBURGH JC,NI B,et al.Pivotal roles of the interleukin-23/T helper 17 cell axis in hepatitis B[J].Liver Int,2012,32(6):894-901.
|
|
[6]GUO W,LUO C,WANG C,et al.Suppression of human and mouse Th17 differentiation and autoimmunity by an endogenous Interleukin23receptor cytokine-binding homology region[J].Int J Biochem Cell Biol,2014,26(55):304-310.
|
|
[7]LI H,HSU HC,WU Q,et al.IL-23 promotes TCR-mediated negative selection of thymocytes through the upregulation of IL-23receptor and RORγt[J].Nat Commun,2014,8(5):4259.
|
|
[8]BELLADONNA ML,RENAULD JC,BIANCHI R,et al.IL-23and IL-12 have overlapping,but distinct,effects on murine dendritic cells[J].J Immunol,2002,168(11):5448-5454.
|
|
[9]IWAKURA Y,ISHIGAME H.The IL-23/IL-17 axis in inflammation[J].J Clin Invest,2006,116(5):1218-1222.
|
|
[10]BUONOMO EL,MADAN R,PRAMOONJAGO P,et al.Role of interleukin 23 signaling in Clostridium difficile colitis[J].J Infect Dis,2013,208(6):917-920.
|
|
[11]TOUSSIROT E.The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases[J].Inflamm Allergy Drug Targets,2012,11(2):159-168.
|
|
[12]CHOI IK,LI Y,OH E,et al.Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-γand TNF-α-co-producing T cell-mediated antitumor immunity[J].PLoS One,2013,8(7):e67512.
|
|
[13]SHIME H,YABU M,AKAZAWA T,et al.Tumor-secreted lactic acid promotes IL-23/IL-17 proinflammatory pathway[J].J Immunol,2008,80(11):7175-7183.
|
|
[14]ZAMARRON BF,CHEN W.Dual roles of immune cells and their factors in cancer development and progression[J].Int J Biol Sci,2011,7(5):651-658.
|
|
[15]WANG Q,ZHOU J,ZHANG B,et al.Hepatitis B virus induces IL-23 production in antigen presenting cells and causes liver damage via the IL-23/IL-17 axis[J].PLoS Pathog,2013,9(6):e1003410.
|
|
[16]WANG Q,ZHENG Y,HUANG Z,et al.Activated IL-23/IL-17pathway closely correlates with increased Foxp3 expression in livers of chronic hepatitis B patients[J].BMC Immunol,2011,12(25):1-9.
|
|
[17]XIA L,TIAN D,HUANG W,et al.Upregulation of IL-23 expression in patients with chronic hepatitis B is mediated by the HBx/ERK/NF-κB pathway[J].J Immunol,2012,188(2):753-764.
|
|
[18]XU HX,LI XJ,PAN XF,et al.Determinaflon of serum IL-23and its significance in patients with severe chronic hepatitis B[J].Chinese J Exp Clin Virol,2012,26(2):123-124.(in Chinese)许海霞,李学俊,潘兴飞,等.慢性重型乙型肝炎患者血清IL-23水平检测及其意义[J].中华实验和临床病毒学杂志,2012,26(2):123-124.
|
|
[19]ZHANG JY,ZHANG Z,LIN F,et al.Interleukin-17-producing CD4(+)T cells increase with severity of liver damage in patients with chronic hepatitis B[J].Hepatology,2010,51(1):81-91.
|
|
[20]HAO C,WANG J,KANG W,et al.Kinetics of Th17 cytokines during telbivudine therapy in patients with chronic hepatitis B[J].Viral Immunol,2013,26(5):336-342.
|
|
[21]YU C,GONG X,YANG Q,et al.The serum IL-23 level predicts the response to pegylated interferon therapy in patients with chronic hepatitis B[J].Liver Int,2015,35(5):1549-1556.
|
|
[22]ASHRAFI HAFEZ A,AHMADI VASMEHJANI A,BAHARLOU R,et al.Analytical assessment of interleukin-23 and-27 cytokines in healthy people and patients with hepatitis C virus infection(genotypes 1 and 3a)[J].Hepat Mon,2014,14(9):e21000.
|
|
[23]ODIGIE M,OSINUSI A,BARRETT L,et al.Inteleukin-23 promotes interferon-αresponsiveness in hepatitis C virus/HIV-coinfected patients[J].AIDS Res Hum Retroviruses,2014,30(8):775-782.
|
|
[24]HARTOONIAN C,EBTEKAR M,SOLEIMANJAHI H,et al.Effect of immunological adjuvants:GM-CSF(granulocyte-monocyte colony stimulating factor)and IL-23(interleukin-23)on immune responses generated against hepatitis C virus core DNA vaccine[J].Cytokine,2009,46(1):43-50.
|
|
[25]WANG JM,MA CJ,LI GY,et al.Tim-3 alters the balance of IL-12/IL-23 and drives TH17 cells:role in hepatitis B vaccine failure during hepatitis C infection[J].Vaccine,2013,31(18):2238-2245.
|
|
[26]HU P,HU HD,CHEN M,et al.Expression of interleukins-23 and27 leads to successful gene therapy of hepatocellular carcinoma[J].Mol Immunol,2009,46(8-9):1654-1662.
|
|
[27]KUANG DM,PENG C,ZHAO Q,et al.Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells[J].Hepatology,2010,51(1):154-164.
|
|
[28]LI J,LAU G,CHEN L,et al.Interleukin 23 promotes hepatocellular carcinoma metastasis via NF-kappa B induced matrix metalloproteinase 9 expression[J].PLoS One,2012,7(9):e46264.
|
|
[29]YANG CY,MA X,TSUNEYAMA K,et al.IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis:implications for therapy[J].Hepatology,2014,59(5):1944-1953.
|
|
[30]HUSTED TL,BLANCHARD J,SCHUSTER R,et al.Potential role for IL-23 in hepatic ischemia/reperfusion injury[J].Inflamm Res,2006,55(5):177-178.
|
|
[31]WANG X,SUN R,WEI H,et al.High-mobility group box 1(HMGB1)-Toll-like receptor(TLR)4-interleukin(IL)-23-IL-17A axis in drug-induced damage-associated lethal hepatitis:Interaction ofγδT cells with macrophages[J].Hepatology,2013,57(1):373-384.
|
DownLoad: